DaxibotulinumtoxinA for eyelid spasms and one-sided facial spasms
Tests DaxibotulinumtoxinA in adults with blepharospasm or hemifacial spasm previously treated with Botox.
Key facts
- Who runs it
- Montefiore Medical Center
- Where
- The Bronx, United StatesSee the site
- Trial code
- Registry title
- Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 40 people, planned
- Started
- 11 Feb 2025
- Expected to end
- Mar 2027
- Type of study
- Interventional
- Treatments tested
- DaxibotulinumtoxinA
- Record updated
- 23 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with benign essential blepharospasm (BEB, uncontrolled eyelid closing) or hemifacial spasm (HFS, twitching of one side of the face). The summary says people treated with Botox before will switch to Daxxify.
- Age
- 18 years and older.
- Sex
- All sexes can join.
- Disease stage
- BEB or HFS diagnosed by an eye doctor (ophthalmologist). A score of at least 4 out of 8 on the modified Jankovic Rating Scale for Severity/Frequency.
- Earlier treatment
- No past surgery for BEB or HFS. No known neurologic or neuromuscular medicines taken for the whole body.
Main reasons for not taking part
- Under 18 years old
- Pregnant
- Not willing to take part
- Medical reasons that rule out botulinum toxin
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Benign essential blepharospasm (BEB) or hemifacial spasm (HFS) as diagnosed by an ophthalmologist
- No known neurologic or neuromuscular systematic medications
- No history or surgical intervention for BEB or HFS
- Patients are required to have a minimum score of 4 out of 8 on the modified Jankovic Rating Scale for Severity/Frequency
Who cannot take part
- Patients will be excluded if age < 18, are pregnant, are non-willing, or have contra-indications to botulinum toxin
Where in United States
- Montefiore Medical CenterThe Bronx, United StatesContact: Anne Barmettler, MDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:
Read full original descriptionShow less
1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response?
Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.
The group in the trial
- Benign Essential Blepharospasm or Hemifacial SpasmTreatment being tested
Patients with either Benign Essential Blepharospasms or Hemifacial Spasms in accordance with Eligibility criteria.
Treatment: DaxibotulinumtoxinA
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm
- Plain-language title
- DaxibotulinumtoxinA for eyelid spasms and one-sided facial spasmsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 23 April 2026